ATYR
HEALTHCAREAtyr Pharma Inc
$1.04+0.20 (+23.49%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ATYR Today?
No stock-specific AI insight has been generated for ATYR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.64$7.29
$1.04
Fundamentals
Market Cap$102M
P/E Ratio—
EPS$-0.80
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding98.1M
ATYR News
20 articles- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
- aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C MeetingMarketbeat·Mar 12, 2026
- Atyr Pharma: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate UpdateYahoo Finance·Mar 5, 2026
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 20, 2026
- aTyr Pharma to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 18, 2026
- aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary SarcoidosisYahoo Finance·Feb 3, 2026
- Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Jan 11, 2026
- aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 10, 2025
- Atyr Pharma: Q3 Earnings SnapshotYahoo Finance·Nov 6, 2025
- aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate UpdateYahoo Finance·Nov 6, 2025
- Independent Director of aTyr Pharma Paul Schimmel Buys 91% More SharesYahoo Finance·Oct 12, 2025
- aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025Yahoo Finance·Sep 30, 2025
- Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial ResultsYahoo Finance·Sep 17, 2025
- Assessing aTyr Pharma (ATYR) Valuation as Investors Weigh Recent Stock Swings and Future ProspectsYahoo Finance·Sep 17, 2025
- aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis failClinicaltrialsarena·Sep 16, 2025
- Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; aTyr Pharma, Oracle to AdvanceYahoo Finance·Sep 16, 2025
- Sector Update: Health Care Stocks Decline Late AfternoonYahoo Finance·Sep 15, 2025
- Sector Update: Health Care Stocks Advance Premarket MondayYahoo Finance·Sep 15, 2025
- ATyr shares plunge on trial miss in inflammatory lung diseaseBiopharmadive·Sep 15, 2025
All 20 articles loaded
Price Data
Open$0.85
Previous Close$0.84
Day High$1.05
Day Low$0.83
52 Week High$7.29
52 Week Low$0.64
52-Week Range
$0.64$7.29
$1.04
Fundamentals
Market Cap$102M
P/E Ratio—
EPS$-0.80
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding98.1M
About Atyr Pharma Inc
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—